ArticleDiscover oncology2025
Analysis of research hotspots on the detection of vascular endothelial growth factor C and its receptor vascular endothelial growth factor receptor-3 in cervical squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical squamous cell carcinoma (CSCC) remains a prevalent malignancy among women worldwide, with lymphatic metastasis critically influencing prognosis. The vascular endothelial growth factor C (VEGF-C)/vascular endothelial growth factor receptor-3 (VEGFR-3) axis plays a pivotal role in tumour lymphangiogenesis, facilitating lymph node invasion and metastasis. This bibliometric analysis, conducted using CiteSpace, systematically reviewed studies on VEGF-C/VEGFR-3 in CSCC between 2010 and 2025, focusing on publication trends, collaboration networks, co-citation patterns and keyword clustering. Publication activity peaked between 2010 and 2014, declined around 2016 and then moderately rebounded after 2020. China and the USA emerged as leading contributors. Influential studies clarified VEGF-C-mediated signalling (e.g. PI3K/Akt and MAPK/ERK pathways), marking a shift in research from basic mechanisms toward translational strategies, such as molecular imaging, targeted therapy and immunomodulation. These findings highlight the VEGF-C/VEGFR-3 axis as clinically substantial and provide direction for future research into the prediction and treatment of lymphatic metastasis in CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.